The scope of our preclinical anti-hepatitis drug development services ranges from screening libraries to the evaluation of the efficacy, toxicity, and range of action of your compound.
The lack of versatile cell-based antiviral assays has somewhat hampered the development of anti-hepatitis compounds. Our laboratory is working to develop and implement new models to enable research in the anti-hepatitis field.
Hepatitis B virus
Available for your needs is a cell-based model of HBV replication, in which human hepatoma cells stably express a full HBV genome. Compounds blocking the late steps of the HBV life cycle including HBV transcription, translation, encapsidation, reverse transcription, particle assembly and maturation can be identified in this cell line. Levels of viral DNA released into the culture supernatant as well as cytoplasmic viral DNA are monitored by real time quantitative PCR assay. Compound toxicity is examined using the parental hepatoma cell line.
For antiviral profiling of drug candidates, a human hepatoma cell line is transiently transfected with a prototypic, characterized HBV genome, which can be further modified either to include mutations in the reverse transcriptase gene conferring resistance to current therapies or to include relevant viral segments of HBV isolated directly from patient-derived specimens. Detection of cytoplasmic viral DNA is quantified by a PCR-based assay.
Available assets for your studies include:
- A bank of characterized, recombinant HBV isolates
- Characterized (multi-)drug resistant HBV mutants
- Engineering of HBV variants according to your needs
Hepatitis C virus
InPheno offers detection of resistance-associated mutations in clinical specimens by means of population sequencing.